Michael Astrue has been named interim CEO of Epix Pharmaceuticals (Cambridge, Massachusetts). The former president and CEO of Transkaryotic Therapies also will assist the board in its search for a permanent CEO. Astrue succeeds Michael Webb, who has resigned as both CEO and a director of Epix, but remains as a consultant to the company, which is a developer of MRI contrast agents.

No Comments